2
Participants
Start Date
April 6, 2018
Primary Completion Date
July 20, 2018
Study Completion Date
July 20, 2018
GSK2315698 (CPHPC)
GSK2315698 will be administered as 20 milligrams per hour (20 mg/hour) IV infusion (in the vein) for up to 72 hours followed by 60 milligrams (mg) three times daily as SC injection for 8 days. Dose level and frequency will be adjusted according to renal function.
GSK2398852 (unlabeled anti-SAP mAb)
Subjects will be administered up to 490 mg of GSK2398852, IV. Dose level will be adjusted based on emerging imaging data.
89Zr-GSK2398852 (89Zr-labeled anti-SAP mAb)
89Zr-GSK2398852 will be available as solution containing 10 mg 89Zr-GSK2398852 for Infusion. Subjects will be administered 37 (Megabecquerel) MBq radioactive dose of 89Zr-GSK2398852 by the IV route at each dosing session.
GSK Investigational Site, Uppsala
Lead Sponsor
GlaxoSmithKline
INDUSTRY